Immune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 Expression.
作者信息
Inomata Minehiko, Takata Naoki, Mizushima Isami, Azechi Kenji, Hayashi Kana, Tokui Kotaro, Taka Chihiro, Okazawa Seisuke, Kambara Kenta, Imanishi Shingo, Miwa Toshiro, Hayashi Ryuji, Matsui Shoko, Tobe Kazuyuki
机构信息
First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Department of Clinical Oncology, Toyama University Hospital, Toyama, Japan.
出版信息
Cancer Diagn Progn. 2021 Jul 3;1(3):173-177. doi: 10.21873/cdp.10023. eCollection 2021 Jul-Aug.
BACKGROUND/AIM: We conducted a retrospective analysis of the survival durations of 25 patients diagnosed as having non-squamous cell non-small cell lung cancer with negative or low tumor programmed death-ligand 1 (PD-L1) expression treated with immune checkpoint inhibitor (ICI) monotherapy.
PATIENTS AND METHODS
The progression-free (PFS) and overall (OS) survival were calculated from the initiation of ICI monotherapy. The association between the patient characteristics and the PFS was analyzed using Cox proportional hazards model.
RESULTS
The median PFS was 2.6 months, and the 12-month PFS rate was 9.3%. The median OS was 5.5 months, and the 12-month OS rate was 39.8%. A Cox proportional hazards model identified the neutrophil/lymphocyte ratio and presence of liver metastasis as being significantly associated with PFS.
CONCLUSION
Our findings suggest that a subset of patients with non-squamous cell non-small cell lung cancer who show negative or low tumor PD-L1 expression could benefit from ICI monotherapy.
Zotero 插件